Statins and morbidity and mortality in COPD in the COMIC study: A prospective COPD cohort study

BMJ Open Respiratory Research

Volumn 3, Issue 1, 2016, Pages

  Citgez, Emanuel ^a,b   Van Der Palen, Job ^a,b   Koehorst Ter Huurne, Kirsten ^a   Movig, Kris ^a   Van Der Valk, Paul ^a   Brusse Keizer, Marjolein ^a  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 85006226087     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2016-000142     Document Type: Article

References (36)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of disease study 2010. Lancet 2012;380:2095–128.
2. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012;379:1341–51.
3. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378:1015–26.
4. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med 2013;45:291–300.
5. Hillas G, Perlikos F, Tsiligianni I, et al. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis 2015;10:95–109.
6. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:728–35.
7. Krishna RK, Issa O, Saha D, et al. Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review. Pulm Pharmacol Ther 2015;30:134–40.
8. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14:37–44.
9. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009;18:222–32.
10. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009;9:32.
11. Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006–12.
12. Horita N, Miyazawa N, Kojima R, et al. Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies. Respir Res 2014;15:80.
13. Ingebrigtsen TS, Marott JL, Nordestgaard BG, et al. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax 2015;70:33–40.
14. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554–60.
15. Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 2013;126:598–606.
16. Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008;62:1373–8.
17. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA normative aging study. Am J Respir Crit Care Med 2007;176:742–7.
18. Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther 2013;26:212–17.
19. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007;132:1764–71.
20. Lawes CM, Thornley S, Young R, et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012;21:35–40.
21. Søyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279–83.
22. Lee TM, Chen CC, Shen HN, et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci 2009;116:497–505.
23. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014;370:2201–10.
24. Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, et al. Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med 2009;103:601–6.
25. Koehorst-ter Huurne K, Movig K, van der Valk P, et al. Differences in adherence to common inhaled medications in COPD. COPD 2015;12:643–8.
26. Zuur-Telgen MC, Brusse-Keizer MG, Vandervalk PD, et al. Stable state MR-proadrenomedullin level is a strong predictor for mortality in COPD patients. Chest 2013;145:534–41.
27. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J Suppl 1993;16:5–40.
28. van der Lende R, Jansen-Koster EJ, Knijpstra S, et al. [Prevalence of cold in Vlagtwedde and Vlaardingen (computer diagnosis versus doctors’ diagnosis)]. Ned Tijdschr Geneeskd 1975;119:1988–96.
29. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988;93:580–6.
30. Celli B, Jones P, Vestbo J, et al. The multidimensional BOD: association with mortality in the TORCH trial. Eur Respir J 2008;32 (Suppl 52):42S.
31. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–12.
32. Stolz D, Kostikas K, Blasi F, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the “BODE-A” index. Eur Respir J 2014;43:397–408.
33. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009;374:704–11.
34. Puhan MA, Hansel NN, Sobradillo P, et al. Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts. BMJ Open 2012;2:pii:e002152.
35. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11: 449–57.
36. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492–9.